Zetia/Vytorin Capture 12.5% Share Of New Cholesterol-Lowering Scripts

Most of the share gains for the Merck/Schering joint venture are coming at the expense of Pfizer’s Lipitor and Merck’s Zocor, Schering says. Global sales for the joint venture more than doubled to $518 mil. in the second quarter.